From: Applying low coverage whole genome sequencing to detect malignant ovarian mass
Group | Pathology | Number | Ratio |
---|---|---|---|
High grade (34) | Serous cystadenocarcinoma | 18 | 53% |
Mucinous cystadenocarcinoma | 8 | 24% | |
Clear cell carcinoma | 3 | 9% | |
Yolk sac tumor | 1 | 3% | |
Adenoid carcinoma of endometrium | 2 | 6% | |
Granular cell carcinoma | 1 | 3% | |
Low grade (10) | Borderline serous cystadenoma | 4 | 40% |
Borderline mucinous cystadenoma | 3 | 30% | |
Borderline endometrial carcinoma | 2 | 20% | |
Benign (19) | Chocolate cyst | 9 | 47% |
Teratoma | 5 | 26% | |
Mucinous cystadenoma | 3 | 16% | |
Spindle cell tumor | 1 | 5% | |
Tuberculous granuloma | 1 | 5% | |
Age (median, range) | |||
 35 (16-53) | Premenopausal | 23 | 35% |
 62 (46-83) | Postmenopausal | 40 | 63% |
FIGO stage | |||
Ovarian cancers | I | 13 | 30% |
II | 6 | 14% | |
III | 18 | 41% | |
IV | 7 | 16% |